Navigation Links
High dose statins prevent dementia
Date:8/31/2013

Dr Lin said: "Statins are widely used in the older population to reduce the risk of cardiovascular disease. But recent reports of statin-associated cognitive impairment have led the US Food and Drug Administration (FDA) to list statin-induced cognitive changes, especially for the older population, in its safety communications."

He added: "Previous studies had considered statin therapy to exert a beneficial effect on dementia. But few large-scale studies have focused on the impact of statins on new-onset, non-vascular dementia in the geriatric population."

Accordingly, the current study examined whether statin use was associated with new diagnoses of dementia. The researchers used a random sample of 1 million patients covered by Taiwan's National Health Insurance. From this they identified 57,669 patients aged >65 years who had no history of dementia in 1997 and 1998. The analysis included pre-senile and senile dementia but excluded vascular dementia.

There were 5,516 new diagnoses of dementia during approximately 4.5 years of follow-up. The remaining 52,153 patients aged >65 formed the control group. Subjects were divided into tertiles according to their mean daily equivalent1 dosage and total (across the entire follow up period) equivalent dosage.

The adjusted hazard ratios (HRs) for dementia were significantly inversely associated with increased daily or total equivalent statin dosage. The HRs for the three tertiles of mean equivalent daily dosage (lowest to highest) were 0.622, 0.697 and 0.419 vs control (p<0.001 for trend). The HRs for the three tertiles of total equivalent dosage (lowest to highest) were 0.773, 0.632 and 0.332 vs control (p<0.001 for trend). The protective effect of statins remained in different age, gender and cardiovascular risk subgroups.

Dr Lin said: "The adjusted risks for dementia were significantly inversely associated with increased total or daily equivalent statin dosage. Patients who received the highest total equivalent doses of statins had a 3-fold decrease in the risk of developing dementia. Similar results were found with the daily equivalent statin dosage."

He added: "It was the potency of the statins rather than their solubility (lipophilic or hydrophilic) which was a major determinant in reducing dementia. High potency statins such as atorvastatin and rosuvastatin showed a significant inverse association with developing dementia in a dose-response manner. Higher doses of high potency statins gave the strongest protective effects against dementia."

Dr Lin continued: "The results were consistent when analysing daily doses of different kinds of statins. Almost all the statins (except lovastatin) decreased the risk for new onset dementia when taken at higher daily doses. A high mean daily dosage of lovastatin was positively associated with the development of dementia, possibly because lovastatin is a lipophilic statin while the anti-inflammatory cholesterol lowering effect of lovastatin is not comparable to that of atorvastatin and simvastatin."

Dr Lin concluded: "To the best of our knowledge, this was the first large-scale, nation-wide study which examined the effect of different statins on new onset dementia (except vascular dementia) in an elderly population. We found that high doses of statins, particularly high potency statins, prevent dementia."


'/>"/>

Contact: Celine Colas
press@escardio.org
44-773-005-7146
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Statins prevent cancer in heart transplant recipients
2. Statins May Help Prevent Enlarged Prostate: Study
3. Are Statins Less Helpful for Women?
4. Turning off key piece of genetic coding eliminates toxic effect of statins, SLU research finds
5. Statins Heart Benefits Outweigh Diabetes Risk: Study
6. Statins Wont Hurt, Might Even Help, Your Pancreas: Study
7. New Drug May Help Those Who Cant Take Statins
8. Statins May Cut Risk of Death From Cancer, Study Suggests
9. Statins have potential to treat an autoimmune clotting disorder called antiphospholipid syndrome
10. Statins Plus Exercise Best at Lowering Cholesterol, Study Finds
11. UT MD Anderson study finds link between statins and improved survival in inflammatory breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... Standard Process is ushering in a new era ... North Carolina Research Campus (NCRC) in Kannapolis, North Carolina and by announcing a new ... fall of this year, occupying over 10,000 square feet on the first floor of ...
(Date:7/27/2017)... ... 2017 , ... For bicycling enthusiasts around the globe, Germany's famous Rad am ... against a backdrop of tree-lined hills at the Nürburgring, a Formula One arena known ... Ring consists of some 73 curves, stretching out over more than 500 meters of ...
(Date:7/27/2017)... (PRWEB) , ... July 28, 2017 , ... ... Syngenta on an upcoming episode of the award-winning television series, American Famer, scheduled ... on RFD-TV. , Syngenta is dedicated to helping humanity face its toughest ...
(Date:7/27/2017)... OH (PRWEB) , ... July 27, 2017 , ... ... Electronic Visit Verification to State Medicaid programs, Managed Care Organizations and Home Care ... 2017. , The MEDsys platform, VinCENT, provides technology solutions to over 1,000 agencies ...
(Date:7/27/2017)... ... 2017 , ... GAFFEY Healthcare, a leading provider of revenue ... Vice President of Revenue Cycle Business Services and Suzanne Dusak to Vice President ... officer (CEO). , Elrene has been with company since Oct 2014 and previously ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017 Zymo Research Corp., also known as ,The Epigenetics Company, ... aging in a precise manner using the myDNAge ™ test. Based ... professor of human genetics and biostatistics at the David Geffen School ... , Zymo Research,s proprietary DNAge ™ technology is used to analyze ... ...
(Date:7/11/2017)... JERUSALEM , July 11, 2017 Oramed ... ), a clinical-stage pharmaceutical company focused on the development ... U.S. Food and Drug Administration (FDA) has agreed to ... successfully completed Phase IIb trial of its oral insulin ... The Phase IIb trial met primary and secondary endpoints ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences ... Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. ... Limited, a leading Chinese Internet services provider, and joined ... advance multiple infectious disease product programs targeting antibiotic resistant ... Founded by Dr. Rodolphe Barrangou ...
Breaking Medicine Technology: